The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Also Read: Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA-editing ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The results of the head-to-head trial come days after CVS Health's decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favoring Wegovy. While Lilly's drug ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Trump also reiterated his long-standing criticism of companies that own pharmacy benefit managers, like CVS and Cigna ... Gilead climbed 7.1% and Eli Lilly was up 2.9%. The directive also urges ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...